DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug

  title={DUEXIS{\textregistered} (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug},
  author={Alfonso E. Bello},
  journal={Therapeutic Advances in Musculoskeletal Disease},
  pages={327 - 339}
  • A. Bello
  • Published 25 April 2012
  • Medicine
  • Therapeutic Advances in Musculoskeletal Disease
Chronic pain conditions affect at least 116 million US adults and more than one-third of adults worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used extensively for the treatment of chronic pain due to their efficacy as anti-inflammatory and analgesic agents. Gastrointestinal toxicity is the most well known adverse effect of NSAID therapy and it may manifest as dyspepsia, ulcers, or bleeding. Current guidelines for the management of patients who require NSAIDs for chronic pain and… 

Figures and Tables from this paper

Fixed-Dose Ibuprofen/Famotidine: A Review of Its Use to Reduce the Risk of Gastric and Duodenal Ulcers in Patients Requiring NSAID Therapy

  • E. Deeks
  • Medicine
    Clinical Drug Investigation
  • 2013
The fixed-dose combination of ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents.

Formulation and Evaluation of Fixed-Dose Combination Immediate Release Tablets of Ibuprofen and Famotidine through Quality by Design Approach

To pursue the study, combination of ibuprofen 600 mg and famotidine 20 mg tablets were prepared by direct compression technique, which is unique in Bangladesh, and the selected formulation was compared to FDA regulated QC parameters and proved its superiority over conventional market products.

Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies

A case report of a patient experiencing a gastric ulcer following NSAIDs use is presented and some of the risk factors and potential strategies for prevention of upper GI mucosal injuries and associated bleeding following NSAID use are examined.

Use of NSAIDs in treating patients with arthritis

In patients with risk factors for NSAID toxicity, using the lowest dose of a drug with a short half-life only when it is needed is likely to be the safest treatment option.

Proton pump inhibitors in acid-related diseases. Issues in diagnosis, treatment and outcome

There is an apparent underutilization of PPIs as gastroprotective therapy in patients at elevated risk of PUD when taking certain medication, and the clinical efficacy of PPI therapy may be reduced because of poor adherence.

Management of Osteoarthritis with Avocado/Soybean Unsaponifiables

Osteoarthritis (OA) is a painful and life-altering disease that severely limits the daily activities of millions of Americans, and it is one of the most common causes of disability in the world. With

Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery

This review highlights the overview of conventional therapy and advancements in newer therapeutics including immunotherapy and gene therapy for rheumatoid arthritis and different novel techniques for the delivery of these therapeutics of active and passive targeting are described.

The prevalence of dyspepsia symptoms and its correlation with the quality of life among Qashqai Turkish migrating nomads in Fars Province, Southern Iran

The high prevalence of dyspepsia in Qashqai nomads necessitates educational health programs for the migrating tribes in order to decrease prevalence of this disease.

Fluorescence Spectroscopic Studies of in vitro Interactions of Famotidine and Tapentadol Hydrochloride with Bovine Serum Albumin

The in vitro interactions of Famotidine (FT) and Tapentadol hydrochloride (TAP) with bovine serum albumin (BSA) have been studied by fluorescence emission spectroscopy under different conditions.



Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

The overall rates of successful treatment of ulcers, erosions, and symptoms associated with NSAIDs were similar for the two doses of omeprazole and misoprostol.

Ibuprofen: pharmacology, efficacy and safety

Paediatric use of ibuprofen is reviewed and the main results are that the drug is relatively safe and effective as a treatment of acute pain and fever, and is probably more effective than paracetamol as an antipyretic.

Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Therapeutic trials involving several thousands of patients with peptic ulcer disease confirm that ranitidine 300mg daily administered orally in single or divided doses is at least as effective as cimetidine 800 to 1000mg daily in increasing the rate of healing of duodenal and gastric ulcers.

Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs

The efficacy of omeprazole and misoprostol in healing and preventing ulcers associated with NSAIDs and the presence of fewer than five erosions at each site and not more than mild dyspepsia was compared.

Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.

Diclofenac 50 mg/misoprostol 200 microg t.i.d. are as efficacious as dicl ofenac 75 mg b.i.)d.

Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.

Prevention of NSAID-induced gastroduodenal ulcers.

Misoprostol, PPIs, and double dose H2RAs are effective at preventing chronic NSAID related endoscopic gastric and duodenal ulcers and was the only prophylactic agent documented to reduce ulcer complications.

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.

Treatment with high-dose famotidine significantly reduces the cumulative incidence of both gastric and duodenal ulcers in patients with arthritis receiving long-term NSAID therapy.

Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs

Evidence‐based use of NSAIDs for frequently encountered pain syndromes, with special focus on the adverse effects of this class of agents is evaluated by members of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy.